BRAF: which options do we have for these patients in second line?

12 / 22

BRAF INHIBITION IN mCRC
• Equal activity when analyzed per MSI status, PI3k mutations, prior irinotecan or sideness
• Trend for a benefit in terms of OS (limited due to a high rate of crossover)